Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 3, 2017, Pages

  Bahiru, Ehete ^a   de Cates, Angharad N ^b   Farr, Matthew R B ^b   Jarvis, Morag C ^b   Palla, Mohan ^c   Rees, Karen ^b   Ebrahim, Shah ^d   Huffman, Mark D ^e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ACETYLSALICYLIC ACID; CHOLESTEROL; DRUG COMBINATION;

ADULT; AGED; BIBLIOGRAPHIC DATABASE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAROTID ENDARTERECTOMY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SECONDARY PREVENTION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT DURATION; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DRUG COMBINATION; DRUG EFFECTS; META ANALYSIS; MIDDLE AGED; MORTALITY; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; ASPIRIN; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHOLESTEROL; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85014512491     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009868.pub3     Document Type: Review

References (217)

1. Cho EJ, Kim JH, Sutradhar S, Yunis C, Westergaard M. Proactive multifactorial intervention strategy reduces the risk of cardiovascular disease estimated with region-specific risk assessment models in Pacific Asian patients participating in the CRUCIAL trial. Journal of Korean Medical Science 2013;28:1741-8. 5299365
2. Cho EJ, Kim JH, Sutradhar S, Yunis C, Westergaard M. Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: a CRUCIAL trial subanalysis. Vascular Health and Risk Management 2014;10:145-56. 5299366
3. Hradec J, Zamorano J, Sutradhar S. Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial. Current Medical Research and Opinion 2013;29:589-96. 5299367
4. Kim JH, Zamorano J, Erdine S, Pavia A, Al-Khadra A, Sutradhar S, Yunis C. Reduction in cardiovascular risk using proactive multifactorial intervention versus usual care in younger (< 65 years) and older (≥ 65 years) patients in the CRUCIAL trial. Current Medical Research and Opinion 2013;29:453-63. 5299368
5. Pavia A, Zamorano J, Sutradhar S, Yunis C. Changes in calculated coronary heart disease risk using proactive multifactorial intervention versus continued usual care in Latin-American and non-Latin-American patients enrolled in the CRUCIAL trial. Current Medical Research and Opinion 2012;28:1667-76. 5299369
6. Pavia LA, Erdine S, Zamorano J, Kim JH, Al KA, Westergaard M, et al. Cardiovascular risk factor management: single-pill amlodipine/atorvastatin versus usual care in patients with hypertension and additional risk factors - the CRUCIAL trial. Journal of Hypertension 2010;Conference:e278-9. 3217119
7. Pavia LA, Zamorano J, Kim JH, Erdine S, Al KA, Westergaard M, et al. Treatment strategies for cardiovascular risk factor management in patients with hypertension and additional risk factors-experiences from the usual care arm of the CRUCIAL trial. Journal of Hypertension 2010;Conference:e276-7. 3217120
8. Zamorano J, Erdine S, Pavia A, Kim JH, Al-Khadra A, Westergaard M, et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: The CRUCIAL trial. Current Medical Research and Opinion 2011;27(4):821-33. 3217121
9. Neutel JM, Bestermann WH, Dyess EM, Graff A, Kursun A, Sutradhar S, et al. The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. Journal of Clinical Hypertension 2009;11(1):22-30. 3217123
10. Castellano JM, Sanz G, Peñalvo JL, Bansilal S, Fernández-Ortiz A, Alvarez L, et al. A polypill strategy to improve adherence: results from the FOCUS project. Journal of the American College of Cardiology 2014;64:2071-82. [DOI: 10.1016/j.jacc.2014.08.021]5299370
11. Sanz G, Fuster V, Guzmán L, Guglietta A, Arnáiz JA, Martínez F, et al. The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives. American Heart Journal 2011;165:811-7. 5299371
12. Selak V, Elley C, Crengle S, Wadham A, Rafter N, Bullen C. Polypills for high risk patients: results of a New Zealand randomised controlled trial. Heart Lung and Circulation. 2014; Vol. 23:e13. 5299372
13. Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014;348:g3318. 5299373
14. Selak V, Elley CR, Crengle S, Harwood M, Doughty R, Arroll B, et al. IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care. Contemporary Clinical Trials 2011;32:909-15. 5299374
15. Selak V, Harwood M, Raina EC, Bullen C, Wadham A, Parag V, et al. Polypill-based therapy likely to reduce ethnic inequities in use of cardiovascular preventive medications: findings from a pragmatic randomised controlled trial. European Journal of Preventive Cardiology 2016;23:1537-45. 5299375
16. Laba TL, Hayes A, Lo S, Peiris DP, Usherwood T, Hillis GS, et al. An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial. Medical Journal of Australia 2014;201:671-3. 5299376
17. Laba TL, Howard K, Rose J, Peiris D, Redfern J, Usherwood T, et al. Patient preferences for a polypill for the prevention of cardiovascular diseases. Annals of Pharmacotherapy 2015;49:528-39. 5299377
18. Liu H, Laba TL, Massi L, Jan S, Usherwood T, Patel A, et al. Facilitators and barriers to implementation of a pragmatic clinical trial in Aboriginal health services. Medical Journal of Australia 2015;203:24-7. 5299378
19. Liu H, Massi L, Laba TL, Peiris D, Usherwood T, Patel A, et al. Patients' and providers' perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial. Circulation: Cardiovascular Quality and Outcomes 2015;8:301-8. 5299379
20. Liu H, Patel A, Brown A, Eades S, Hayman N, Jan S, et al. Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk. BMC Public Health 2010;10:458. 5299380
21. Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology 2015;22:920-30. 3217129
22. Truelove M, Patel A, Bompoint S, Brown A, Cass A, Hillis GS, et al. The effect of a cardiovascular polypill strategy on pill burden. Cardiovascular Therapy 2015;33:347-52. 5299381
23. Malekzadeh F, Marshall T, Pourshams A, Gharravi M, Aslani A, Nateghi A, et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. International Journal of Clinical Practice 2010;64(9):1220-7. 3217131
24. Park JS, Shin JH, Hong TJ, Seo HS, Shim WJ, Baek SH, et al. Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong). Drug Design, Development and Therapy 2016;10:2599-609. 5299383
25. Lafeber M, Webster R, Visseren FLj, Bots ML, Grobbee DE, Spiering W, et al. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease. European Journal of Preventive Cardiology 2016;23:1289-97. 5299384
26. PILL CG. An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS One 2011;6(5):e19857. 3217133
27. Soliman EZ, Mendis S, Dissanayake WP, Somasundaram NP, Gunaratne PS, Jayasingne IK, et al. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials 2011;12:3. 3217135
28. Soliman EZ, Mendis S, Dissanayake WP, Somasundaram NP, Gunaratne PS, Jayasingne IK, et al. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials 2011;5:3. 5299385
29. Indian Polycap Study, Yusuf S, Pais P, Afzal R, Xavier D, Teo K, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009;373(9672):1341-51. 3217137
30. Grimm R, Malik M, Yunis C, Sutradhar S, Kursun A, TOGETHER Investigators. Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial. Vascular Health & Risk Management 2010;6:261-71. 3217139
31. Grimm RH, Malik M, Yunis C, Sutradhar S, Kursun A. The critical importance of treating absolute cardiovascular risk as opposed to individual cardiovascular risk factors in isolation. Journal of Clinical Hypertension 2009;Conference:A120-1. 3217140
32. Salam A, Stewart F, Singh K, Thom S, Williams HJ, Patel A, et al. INterpreting the Processes of the UMPIRE Trial (INPUT): protocol for a qualitative process evaluation study of a fixed-dose combination (FDC) strategy to improve adherence to cardiovascular medications. BMJ Open 2013;3:e002313. 5299386
33. Thom S, Field J, Poulter N, Patel A, Prabhakaran D, Stanton A, et al. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. European Journal of Preventive Cardiology 2014;21(2):252-61. [DOI: http://dx.doi.org/10.1177/2047487312463278]5299387
34. Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013;310:918-29. [DOI: 10.1001/jama.2013.277064]3217142
35. Wood F, Salam A, Singh K, Day S, Jan S, Prabhakaran D, et al. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease. BMJ Open 2015;5:e008018. 5299388
36. Wald D, Morris J, Wald N. Randomised polypill crossover trial in people aged 50 and over. PLoS One 2012;7(7):e41297. 3217144
37. Abdellatif AA. Role of single-pill combination therapy in optimizing blood pressure control in high-risk hypertension patients and management of treatment-related adverse events. Journal of Clinical Hypertension (Greenwich) 2012;14:718-26. [DOI: http://dx.doi.org/10.1111/j.1751-7176.2012.00696.x]5299390
38. Agabiti-Rosei E, Manolis A, Zava D, Omboni S, Zodiac Study Group. Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients. Advances in Therapy 2014;31(2):217-33. [DOI: http://dx.doi.org/10.1007/s12325-013-0090-8]5299392
39. Agarwal R, Weir MR. Blood pressure response with fixed-dose combination therapy: comparing hydrochlorothiazide with amlodipine through individual-level meta-analysis. Journal of Hypertension 2013;31(8):1692-701. [DOI: http://dx.doi.org/10.1097/HJH.0b013e32836157be]5299394
40. Anonymous . I take medications for blood pressure, cholesterol and other conditions. I have a two-part question: are there any long-term problems from taking a dozen or so pills a day, and has there been much progress in developing a "polypill" that combines several drugs into a single pill?. Heart Adviser 2010;13:8. 5299396
41. Anonymous . Doubts surround study results touting polypill's benefits. The experimental pill contains four heart medications. Heart Adviser 2011;14:4. 5299398
42. Anonymous . Treating many conditions--with just one pill. The polypill could make your medicines much easier to take. Harvard Women's Health Watch 2012;20:5. 5299400
43. Anonymous . Hypertension: improved therapy adherence after switch to a fixed drug combinations. MMW Fortschritte der Medizin 2012;154:78-9. 5299402
44. Anonymous . Coming soon: many drugs in one pill. Multidrug combinations may make medicines easier to swallow. Harvard Heart Letter 2013;23(7):5. 5299404
45. Anonymous . Combined heart protection for the hypertensive patient. MMW Fortschritte der Medizin 2013;155(1):66-7. 5299406
46. Athyros VG, Katsiki N, Karagiannis A. Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients. Current Medical Research and Opinion 2013;29(7):791-2. [DOI: http://dx.doi.org/10.1185/03007995.2013.805536]5299408
47. Athyros VG, Katsiki N, Karagiannis A, Mikhailidi DP. Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease. Current Pharmaceutical Design 2014;20(40):6299-305. 5299410
48. Bashir S, Sherwani MU, Shabbir I, Batool A. Efficacy of fix dose combination (atorvastatin and amlodipine) in treatment of uncontrolled hypertension and dyslipidemia. Journal of Ayub Medical College Abbottabad 2011;23:97-100. 5299412
49. Becerra V, Gracia A, Desai K, Abogunrin S, Brand S, Chapman R, et al. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. BMJ Open 2015;5(5):e007111. [DOI: http://dx.doi.org/10.1136/bmjopen-2014-007111]5299414
50. Bittencourt MS, Blaha M, Blankstein R, Vargas J, Budoff M, Agatston A, et al. Eligibility for polypill therapy, subclinical atherosclerosis, and cardiovascular events-national implications for the appropriate use of preventive pharmacotherapy: multi-ethnic study of atherosclerosis (MESA). Journal of the American College of Cardiology 2013;1:E813. [DOI: http://dx.doi.org/10.1016/S0735-1097%2813%2960813-X]5299416
51. Bittencourt MS, Blaha MJ, Blankstein R, Budoff M, Vargas JD, Blumenthal RS, et al. Polypill therapy, subclinical atherosclerosis, and cardiovascular events - implications for the use of preventive pharmacotherapy. Journal of the American College of Cardiology 2014;63(5):434-43. [DOI: 10.1016/j.jacc.2013.08.1640]5299418
52. Blank R, Hobbs FDR, Zamorano J, Girerd X. A single-pill combination of amlodipine besylate and atorvastatin calcium (update). Drugs of Today 2007;43:157-77. [DOI: http://dx.doi.org/10.1358/dot.2007.43.3.1079878]5299420
53. Briasoulis A, Bakris G. Initial single-pill combination therapy for cardiovascular risk factor management: it is not just convenience. Journal of Hypertension 2013;31(8):1537-8. [DOI: http://dx.doi.org/10.1097/HJH.0b013e328361d016]5299422
54. Bryant L, Martini N, Chan J, Chang L, Marmoush A, Robinson B, et al. Could the polypill improve adherence? The patient perspective. Journal of Primary Health Care 2013;5(1):28-35. 5299424
55. Carey KM, Comee MR, Donovan JL, Kanaan AO. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke. Annals of Pharmacotherapy 2012;46:688-95. [DOI: http://dx.doi.org/10.1345/aph.1Q621]5299426
56. Cass A, Patel A, Rodgers A. A pragmatic trial of a polypill-based strategy to improve adherence to indicated preventive treatments among people at high cardiovascular disease risk. Nephrology 2013;18:33. [DOI: http://dx.doi.org/10.1111/nep.12121]5299428
57. Castellano JM, Sanz G, Fuster V. Evolution of the polypill concept and ongoing clinical trials. Canadian Journal of Cardiology 2014;30(5):520-6. [DOI: http://dx.doi.org/10.1016/j.cjca.2014.02.016]5299430
58. Castellano JM, Sanz G, Ortiz AF, Garrido E, Bansilal S, Fuster V. A polypill strategy to improve global secondary cardiovascular prevention from concept to reality. Journal of the American College of Cardiology 2014;64(6):613-21. [DOI: 10.1016/j.jacc.2014.06.009]5299432
59. Castellano JM, Bueno H, Fuster V. The cardiovascular polypill: clinical data and ongoing studies. International Journal of Cardiology 2015;201:S8-14. [DOI: http://dx.doi.org/10.1016/S0167-5273%2815%2931027-5]5299434
60. Chae DW, Son M, Kim Y, Son H, Jang SB, Seo JM, et al. Pharmacokinetics of a telmisartan/rosuvastatin fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects. International Journal of Clinical Pharmacology and Therapeutics 2015;53(10):883-9. [DOI: http://dx.doi.org/10.5414/CP202412]5299436
61. Chinese Expert, Consensus, Recommendation Group on the Development of Cardiovascular Disease Polypill in China. Consensus recommendation on the development of cardiovascular disease polypill in China. Chung Hua Hsin Hsueh Kuan Ping Tsa Chih 2013;41(2):91-3. 5299438
62. Chrysant SG, Chrysant GS. Future of polypill use for the prevention of cardiovascular disease and strokes. The American Journal of Cardiology 2014;114(4):641-5. [DOI: 10.1016/j.amjcard.2014.05.049]5299440
63. Crunkhorn S. Trial watch: dual-acting combination meets heart failure end point. Nature Reviews Drug Discovery 2012;11:740. [DOI: http://dx.doi.org/10.1038/nrd3855]5299442
64. Dabhadkar KC, Bellam N. Polypill strategy for primary prevention of cardiovascular disorders. Drugs Today 2013;49:317-24. [DOI: 10.1358/dot.2013.49.5.1950148]5299444
65. de Cates AN, Farr MRB, Wright N, Jarvis MC, Rees K, Ebrahim S, et al. Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD009868.pub2]5299446
66. Delgado-Montero A, Zamorano JL. Atorvastatin calcium plus amlodipine for the treatment of hypertension. Expert Opinion on Pharmacotherapy 2012;13(18):2673-85. [DOI: 10.1517/14656566.2012.742064]5299448
67. Dimitrov Y, Baguet JP, Hottelart C, Marboeuf P, Tartiere JM, Ducher M, et al. Is there a BP benefit of changing the time of aspirin administration in treated hypertensive patients?. European Journal of Preventive Cardiology 2012;19:706-11. [DOI: http://dx.doi.org/10.1177/1741826711418165]5299450
68. Dresser G, Nelson S, Mahon J, Zou G, Vandervoort M, Wong C, et al. Single pill combination therapy for treatment of hypertension in the combined stitch and STITCH2 study populations. Journal of Clinical Hypertension 2012; Vol. 14. 5299452
69. Dresser GK, Nelson SA, Mahon JL, Zou G, Vandervoort MK, Wong CJ, et al. Simplified therapeutic intervention to control hypertension and hypercholesterolemia: a cluster randomized controlled trial (STITCH2). Journal of Hypertension 2013;31(8):1702-13. [DOI: http://dx.doi.org/10.1097/HJH.0b013e3283619d6a]5299454
70. Elley CR, Gupta AK, Webster R, Selak V, Jun M, Patel A, et al. The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials. PLoS ONE 2012;7:e52145. [DOI: http://dx.doi.org/10.1371/journal.pone.0052145]5299456
71. Fedacko J, Pella D, Jarcuska P, Sabol F, Kmec J, Lopuchovsky T, et al. Slovak trial on cardiovascular risk reduction following national guidelines with CaDUET (the STRONG DUET study). Advances in Therapy 2013;30(1):60-70. [DOI: http://dx.doi.org/10.1007/s12325-012-0075-z]5299458
72. Feldman RD, Flack J, Howes L, Jenssen T, Reeves R, Shi H, et al. Impact of age and gender on blood pressure and low-density lipoprotein cholesterol reduction: results of a pooled analysis. Current Medical Research and Opinion 2012;28:1421-33. 5299460
73. Feldman RD, Nattel S. Increasing appreciation for the role of single-pill combinations for the prevention of atherosclerotic disease: a pro-polypill polemic. Canadian Journal of Cardiology 2014;30(5):517-9. [DOI: http://dx.doi.org/10.1016/j.cjca.2014.03.011]5299462
74. Feng Y, Xu H, Chen K. Natural polypill Xuezhikang: its clinical benefit and potential multicomponent synergistic mechanisms of action in cardiovascular disease and other chronic conditions. Journal of Alternative and Complementary Medicine 2012;18:318-28. [DOI: http://dx.doi.org/10.1089/acm.2011.0187]5299464
75. Galindo-Ocana J, Bernabeu-Wittel M, Formiga F, Fuertes-Martin A, Baron-Franco B, Murcia-Zaragoza JM, et al. Effects of renin-angiotensin blockers/inhibitors and statins on mortality and functional impairment in polypathological patients. European Journal of Internal Medicine 2012;23:179-84. [DOI: 10.1016/j.ejim.2011.06.004]5299466
76. Gaziano JM. Progress with the polypill?. JAMA 2013;310(9):910-1. [DOI: http://dx.doi.org/10.1001/jama.2013.277066]5299468
77. Holzgreve H. Health and longevity by one tablet daily. Fiction and hard facts on the polypill. MMW Fortschritte der Medizin 2014;156(1):55-7. 5299470
78. Huang Z, Chen C, Li S, Kong F, Shan P, Huang W. Combined treatment with amlodipine and atorvastatin calcium reduces circulating levels of intercellular adhesion molecule-1 and tumor necrosis factor-alpha in hypertensive patients with prediabetes. Frontiers in Aging Neuroscience 2016;8:206. [DOI: http://dx.doi.org/10.3389/fnagi.2016.00206]5299472
79. Huffman MD, Bhatnagar D. Novel treatments for cardiovascular disease prevention. Cardiovascular Therapeutics 2012;30(5):257-63. [DOI: 10.1111/j.1755-5922.2011.00280.x]5299474
80. Huffman MD, Yusuf S. Polypills: essential medicines for cardiovascular disease secondary prevention?. Journal of the American College of Cardiology 2014;63(14):1368-70. [DOI: http://dx.doi.org/10.1016/j.jacc.2013.08.1665]5299476
81. Ito K, Shrank WH, Avorn J, Patrick AR, Brennan TA, Antman EM, et al. Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction. Health Services Research 2012;47:2097-117. [DOI: http://dx.doi.org/10.1111/j.1475-6773.2012.01462.x]5299478
82. Ivanovic B, Tadic M. Fixed combination of amlodipine/atorvastatin: from mechanisms to trials. Journal of Cardiovascular Pharmacology and Therapeutics 2013;18(6):544-9. [DOI: http://dx.doi.org/10.1177/1074248413492907]5299480
83. Jadhav U, Hiremath J, Namjoshi DJ, Gujral VK, Tripathi KK, Siraj M, et al. Blood pressure control with a single-pill combination of indapamide sustained-release and amlodipine in patients with hypertension: The EFFICIENT Study. PLoS One 2014;9(4):6. [DOI: 10.1371/journal.pone.0092955]5299482
84. Jang JY, Lee SH, Kim BS, Seo HS, Kim WS, Ahn Y, et al. Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients. Korean Circulation Journal 2015;45(3):225-33. [DOI: 10.4070/kcj.2015.45.3.225]5299484
85. Jaques H. The polypill concept: the story so far. [Erratum appears in European Heart Journal 2012 Mar; 33(5):551]. European Heart Journal 2011;32:2471-2. 5299486
86. Kawashiri MA, Sakata K, Gamou T, Kanaya H, Miwa K, Ueda K, et al. Impact of combined lipid lowering with blood pressure control on coronary plaque regression: rationale and design of MILLION study. Heart Vessels 2015;30(5):580-6. [DOI: http://dx.doi.org/10.1007/s00380-014-0522-7]5299488
87. Kereiakes DJ, Chrysant SG, Izzo JL, Littlejohn T, Melino M, Lee J, et al. Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovascular Diabetology 2012;11:13. [DOI: 10.1186/1475-2840-11-134]5299490
88. Khaled SA, Burley JC, Alexander MR, Yang J, Roberts CJ. 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. Journal of Controlled Release 2015;217:308-14. [DOI: 10.1016/j.jconrel.2015.09.028]5299492
89. Laba TL, Howard K, Rose J, Jan S. Using DCE to assess adherence and treatment preferences for combination therapies for cardiovascular disease. Global Heart 2014;1:e44. [DOI: http://dx.doi.org/10.1016/j.gheart.2014.03.1367]5299494
90. Laba TL, Hayes A, Jan S, Rodgers A, Patel A, Cass A, et al. Can a CVD polypill save money in the 'real world'?. Value in Health 2014;17(7):A482. [DOI: http://dx.doi.org/10.1016/j.jval.2014.08.1398]5299496
91. Lafeber M, Spiering W, Bots ML, De Valk V, Visseren FL, Grobbee DE. Cardiovascular polypill in high risk patients. Nederlands Tijdschrift Voor Geneeskunde 2011;155:A3070. 5299498
92. Lafeber M, Spiering W, Singh K, Guggilla RK, Patil V, Webster R. The cardiovascular polypill in high-risk patients. European Journal of Preventive Cardiology 2012;19:1234-42. [DOI: http://dx.doi.org/10.1177/1741826711428066]5299500
93. Lafeber M, Grobbee DE, Spiering W, Van der Graaf Y, Bots ML, Visseren FL. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus. European Journal of Preventive Cardiology 2013;20(5):771-8. [DOI: http://dx.doi.org/10.1177/2047487312449587]5299502
94. Lafeber M, Spiering W, Van der Graaf Y, Nathoe H, Bots ML, Grobbee DE, et al. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease. American Heart Journal 2013;166(2):282-9.e1. [DOI: http://dx.doi.org/10.1016/j.ahj.2013.04.011]5299504
95. Lafeber M, Grobbee DE, Bots ML, Thom S, Webster R, Rodgers A, et al. The Evening versus Morning Polypill Utilization Study: The TEMPUS rationale and design. European Journal of Preventive Cardiology 2014;21(4):425-33. [DOI: http://dx.doi.org/10.1177/2047487313476961]5299506
96. Lafeber M, Spiering W, Grobbee DE, Bots ML, Webster R, Thom S, et al. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk. Circulation 2014;129:AP381. 5299508
97. Lafeber M, Stanton A, Thom S, Hughes A, Grobbee DE, Rodgers A, et al. A randomized controlled trial of a cardiovascular fixed-dose combination pill (polypill) treatment strategy compared with usual care on carotid intima media thickness progression in individuals at high risk of cardiovascular disease. Circulation 2014;129:AP445. 5299510
98. Lafeber M, Grobbee DE, Schrover IM, Thom S, Webster R, Rodgers A, et al. The effect of morning or evening use of a fixed-dose combination pill (polypill) on LDL-cholesterol, ambulatory blood pressure and adherence in patients with cardiovascular disease. European Journal of Preventive Cardiology 2014;1:S132. [DOI: http://dx.doi.org/10.1177/2047487314534585]5299512
99. Lafeber M, Grobbee DE, Schrover IM, Thom S, Webster R, Rodgers A, et al. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial. International Journal of Cardiology 2015;181:193-9. [DOI: http://dx.doi.org/10.1016/j.ijcard.2014.11.176]5299514
100. Lafeber M, Spiering W, Visseren FLJ, Grobbee DE. Multifactorial prevention of cardiovascular disease in patients with hypertension: the cardiovascular polypill. Current Hypertension Reports 2016;18(5):40. [DOI: 10.1007/s11906-016-0648-3]5299516
101. Law MG. Cardiovascular complications of HIV: an overview of risk and a novel approach to prevention - the HIV polypill study. Current Opinion in HIV and AIDS 2006;1(6):482-7. [DOI: 10.1097/01.coh.0000247389.08485.87]5299518
102. Liu H, Massi L, Laba T, Jan S. Understanding adherence to a cardiovascular polypill strategy-a process evaluation of a pragmatic clinical trial. Global Heart 2014;1:e118. [DOI: http://dx.doi.org/10.1016/j.gheart.2014.03.1644]5299520
103. Liu H, Massi L, Laba TL, Peiris D, Usherwood T, Patel A, et al. Patients' and providers' perspectives of a polypill strategy to improve cardiovascular prevention in Australian Primary Health Care. Circulation: Cardiovascular Quality and Outcomes 2015;8(3):301-8. [DOI: http://dx.doi.org/10.1161/CIRCOUTCOMES.115.001483]5299522
104. Marazzi G, Pelliccia F, Campolongo G, Cacciotti L, Poggi S, Tanzilli A, et al. Greater cardiovascular risk reduction with once-daily fixed combination of three antihypertensive agents and statin versus free-drug combination: The ALL-IN-ONE trial. International Journal of Cardiology 2016;222:885-7. [DOI: http://dx.doi.org/10.1016/j.ijcard.2016.07.163]5299524
105. Mishchenko O, Bezditko N, Adonkina V, Tkachova O. Pharmacoeconomic grounding of using polypill amlodipine with atorvastatin versus monodrugs in patients with hypertension and dyslipidemia in Ukraine. Value in Health 2014;17(7):A475. [DOI: http://dx.doi.org/10.1016/j.jval.2014.08.1356]5299526
106. Mossello E. Targeting vascular risk factors in older adults: from polypill to personalized prevention. JAMA Internal Medicine 2015;175(12):1949-50. [DOI: http://dx.doi.org/10.1001/jamainternmed.2015.5941]5299528
107. Neutel JM, Bestermann WH, Dyess EM, Graff A, Kursun A, Sutradhar S, et al. The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. Journal of Clinical Hypertension 2009;11(1):22-30. [DOI: 10.1111/j.1751-7176.2008.00058.x]5299530
108. Nguyen C, Cheng-Lai A. The polypill a potential global solution to cardiovascular disease. Cardiology in Review 2013;21:49-54. [DOI: 10.1097/CRD.0b013e3182755429]5299532
109. Oliveras Vila T, Ferrer Massot M, Curos Abadal A, Rueda Sobella F, Serra Flores J, Carrillo Suarez, et al. Real-life use of the polypill components (ASA+ACEI+statins) after an acute coronary syndrome and long-term mortality. International Journal of Cardiology 2014;177(1):209-10. [DOI: http://dx.doi.org/10.1016/j.ijcard.2014.09.029]5299534
110. Reiner Z. Polypill is not a 'vaccine-like' solution for primary cardiovascular disease prevention in all parts of the world. Journal of Epidemiology and Community Health 2013;67(12):981-2. [DOI: 10.1136/jech-2013-203220]5299536
111. Selak V, Crengle S, Elley CR, Wadham A, Harwood M, Rafter N, et al. Recruiting equal numbers of indigenous and non-indigenous participants to a 'polypill' randomized trial. International Journal for Equity in Health 2013;12:44. [DOI: http://dx.doi.org/10.1186/1475-9276-12-44]5299538
112. Selak V, Bullen C, Stepien S, Arroll B, Bots M, Bramley D, et al. Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease. European Journal of Preventive Cardiology 2016;23(13):1393-400. [DOI: http://dx.doi.org/10.1177/2047487316638216]5299540
113. Sepanlou SG, Farzadfar F, Jafari E, Danaei G. Cardiovascular disease prevention using fixed dose pharmacotherapy in Iran: updated meta-analyses and mortality estimation. Archives of Iranian Medicine 2012;15(9):531-7. [DOI: http://dx.doi.org/012159/AIM.004]5299542
114. Sigamani A, Pais P, Xavier D, Koon T, Xavier F, Girish P, et al. Comparison of risk factor reduction and tolerability of a full dose versus low dose of a polypill (polycap) in individuals at high risk of cardiovascular diseases: a phase II, double blind randomized trial. Circulation 2012;125(19):e803. [DOI: http://dx.doi.org/10.1161/CIR.0b013e31824fcdb3]5299544
115. Simonyi G, Ferenci T. One year persistence of atorvastatin and amlodipine fixed dose combination versus atorvastatin therapy. Orvosi Hetilap 2016;157(11):425-9. [DOI: http://dx.doi.org/10.1556/650.2016.30401]5299546
116. Son H, Roh H, Lee D, Chang H, Kim J, Yun C, et al. Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects. Clinical Therapeutics 2013;35(7):915-22. [DOI: http://dx.doi.org/10.1016/j.clinthera.2013.05.016]5299548
117. Tanaka M, Nishimura R, Nishimura T, Kawai T, Meguro S, Irie J, et al. Effect of single tablet of fixed-dose amlodipine and atorvastatin on blood pressure/lipid control, oxidative stress, and medication adherence in type 2 diabetic patients. Diabetology and Metabolic Syndrome 2014;6:8. [DOI: 10.1186/1758-5996-6-56]5299550
118. Truelove M, Webster R, Bompoint S, Patel A. Impact of pill burden on the effects of a polypill-based strategy on use of indicated medications in people with or at high risk of cardiovascular disease. Global Heart 2014;1:e298. [DOI: http://dx.doi.org/10.1016/j.gheart.2014.03.2303]5299552
119. Wald NJ, Luteijn JM, Morris JK, Taylor D, Oppenheimer P. Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke. European Journal of Epidemiology 2016;31(4):415-26. [DOI: 10.1007/s10654-016-0122-1]5299554
120. Wang YQ, Hu Z, Yang Y, Gao PJ. Effect of amlodipine and amlodipine plus atorvastatin on impaired vascular function in patients with hypertension. Journal of Hypertension 2012;30:e163. [DOI: http://dx.doi.org/10.1097/01.hjh.0000420580.36849.9c]5299556
121. Webster R, Patel A, Billot L, Cass, A, Burch C, Neal B, et al. Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: the SPACE Collaboration. International Journal of Cardiology 2013;170(1):30-5. [DOI: http://dx.doi.org/10.1016/j.ijcard.2013.10.007]5299558
122. Webster R, Rodgers A. PREVENTION coronary artery calcium and polypill therapy. Nature Reviews Cardiology 2014;11(1):7. [DOI: 10.1038/nrcardio.2013.185]5299560
123. Webster R, Rodgers A. Polypill: progress and challenges to global use: update on the trials and policy implementation. Current Cardiology Reports 2015;17(12):121. [DOI: http://dx.doi.org/10.1007/s11886-015-0673-x]5299562
124. Webster R, Bullen C, Patel A, Rodgers A, Selak V, Thom S. Impact of cardiovascular polypill based therapy on healthy lifestyle behavior. European Journal of Preventive Cardiology 2015;1:S150. [DOI: http://dx.doi.org/10.1177/2047487315586744]5299564
125. Webster R, Patel A, Selak V, Billot L, Bots ML, Brown A, et al. Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: a prospective, individual patient data meta-analysis of 3140 patients in six countries. International Journal of Cardiology 2016;205:147-56. [DOI: http://dx.doi.org/10.1016/j.ijcard.2015.12.015]5299566
126. Webster R, Rodgers A. Polypill treatments for cardiovascular diseases. Expert Opinion on Drug Delivery 2016;13(1):1-6. [DOI: http://dx.doi.org/10.1517/17425247.2016.1111869]5299568
127. Wei XL, Zou GY, Gong WW, Yin J, Yu YX, Walley J, et al. Cardiovascular disease risk reduction in rural China: a clustered randomized controlled trial in Zhejiang. Trials 2013;14:10. [DOI: 10.1186/1745-6215-14-354]5299570
128. Wijns W, Rusinaru D. "De-risking" risk reduction should coronary artery calcium scoring be the gatekeeper to preventive pharmacotherapy with the polypill?. Journal of the American College of Cardiology 2014;63(5):444-6. [DOI: 10.1016/j.jacc.2013.09.044]5299572
129. Wiley B, Fuster V. The concept of the polypill in the prevention of cardiovascular disease. Annals of Global Health 2014;80(1):24-34. [DOI: 10.1016/j.aogh.2013.12.008]5299574
130. Xing DM, Zhang JH, Li L, Zhu MJ, Shang HC. Intervention effects and safety of cardiovascular polypill for the relevant risk factors of coronary heart disease: a systematic review. Chinese Journal of Evidence-Based Medicine 2013;13:446-51. [DOI: http://dx.doi.org/10.7507/1672-2531.20130077]5299576
131. Zeng R, Wang M, Zhang L. Is time an important problem in management of hypertension and hypercholesterolemia by using an amlodipine-atorvastatin single pill combination?. Medical Science Monitor 2016;22:2648-55. [DOI: 10.12659/msm.896843]5299578
132. Zomer E, Owen A, Magliano DJ, Ademi Z, Reid CM, Liew D. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis. American Journal of Cardiovascular Drugs 2013;13(2):121-8. [DOI: http://dx.doi.org/10.1007/s40256-013-0019-2]5299580
133. Fommei E, Ghione S, Biagini S, Corrao G, Mancia G. A proposal for the idea of a flexible-combination polypill in arterial hypertension. Journal of Hypertension. 2015; Vol. 33:e258. 5299582
134. NCT00530946 . A randomized study to evaluate efficacy and safety of a fixed combination therapy of amlodipine and atorvastatin [A multi-center, randomized study to evaluate efficacy and safety of a fixed combination therapy of amlodipine and atorvastatin in the treatment of concurrent hypertension and hyper-LDL-cholesterolemia]. clinicaltrials.gov/ct2/show/NCT00530946 (first received 13 September 2007). 5299584
135. NCT01004705 . Cardiovascular fixed dose combination pill: a pharmacodynamic study of a fixed dose combination of acetylsalicylic acid, simvastatin, and ramipril in subjects with elevated LDL cholesterol. clinicaltrials.gov/ct2/show/NCT01004705 (first received 23 October 2009). 5299586
136. NCT01005290 . Cardiovascular fixed dose combination pill: a pharmacodynamic interaction study to evaluate the effect of a fixed dose combination of acetylsalicylic acid, simvastatin and ramipril (cardiovascular fixed dose combination pill) on blood pressure. clinicaltrials.gov/ct2/show/NCT01005290 (first received 22 October 2009). 5299588
137. NCT01362218 . Cardiovascular fixed combination pill ASR: pharmacodynamic clinical trial of a fixed dose combination of acetylsalicylic acid, simvastatin, and ramipril (cardiovascular polypill) on LDL cholesterol. clinicaltrials.gov/ct2/show/NCT01362218 (first received 26 May 2011). 5299590
138. NCT01406431 . A single dose, sequence-randomized, open-label, 2x2 crossover study to compare pharmacokinetics between pitavastatin and valsartan co-administration and Livalo® fixed combination drug in healthy male subjects. clinicaltrials.gov/ct2/show/NCT01406431 (first received 26 July 2011). 5299592
139. NCT01764178 . A single dose, sequence-randomized, open-label, 2x2 crossover study to compare pharmacokinetics between pitavastatn and valsartan co-administration and Livalo complex product in healthy male subjects. clinicaltrials.gov/ct2/show/NCT01764178 (first received 1 January 2013). 5299594
140. NCT02075619 . An open-label, randomized, single dose, three-way crossover, six sequence pilot study to evaluate the relative bioavailability of one amlodipine 10mg tablet and rosuvastatin 20mg tablet to two fixed dose combination tablet formulations of amlodipine (10mg) and rosuvastatin (20mg) in healthy adult male and female subjects under fasting conditions. clinicaltrials.gov/ct2/show/NCT02075619 (first received 27 February 2014). 5299596
141. NCT02569814 . A study to compare the pharmacokinetics and safety of a fixed dose combination of fimasartan/amlodipine/rosuvastatin. clinicaltrials.gov/ct2/show/NCT02569814 (first received 5 October 2015). 5299598
142. NCT02662894 . Efficacy of fixed-dose combination of valsartan + rosuvastatin versus their isolated components for hypertension and dyslipidemia. clinicaltrials.gov/ct2/show/NCT02662894 (first received 23 November 2015). 5299600
143. NCT02791958 . Pharmacodynamic equivalence study of ramipril 10 mg and atorvastatin 40 mg administered as a cardiovascular fixed dose combination pill AAR as compared to monotherapy with the reference products Altace® 10 mg and Lipitor® 40 mg. clinicaltrials.gov/ct2/show/NCT02791958 (first received 15 February 2016). 5299602
144. NCT02842359 . Efficacy evaluation of metabolic, anti-inflammatory, and antioxidative factors of irbesartan/atorvastatin fixed-dose combination in type 2 diabetic patients diagnosed with hyperlipidemia and hypertension, with adequately controlled blood glucose levels. clinicaltrials.gov/ct2/show/NCT02842359 (first received 20 July 2016). 5299604
145. Hayek A, Joshi R, Usherwood T, Webster R, Kaur B, Saini B, et al. An integrated general practice and pharmacy-based intervention to promote the use of appropriate preventive medications among individuals at high cardiovascular disease risk: protocol for a cluster randomized controlled trial. Implementation Science 2016;11:129. 5299606
146. Joshi R, Patel A, Peiris D, Saini B, Usherwood T, Armor C, et al. INTegrated Electronic General practice support tool, phaRmacy led intervention And combination Therapy Evaluation trial (INTEGRATE). Heart Lung and Circulation. 2015:S385. 5299607
147. NCT01646437 . The International Polycap Study-3. clinicaltrials.gov/ct2/show/NCT01646437 (first received 10 July 2012). 3217204
148. NCT01826019 . Heart Outcomes Prevention and Evaluation 4 (HOPE-4). clinicaltrials.gov/ct2/show/NCT01826019 (first received 31 March 2013). 5299609
149. NCT02278471 . The SCCS polypill pilot trial. clinicaltrials.gov/ct2/show/NCT02278471 (first received 13 October 2014). 5299611
150. NCT02596126 . SEcondary prevention of Cardiovascular disease in the Elderly trial (SECURE). clinicaltrials.gov/ct2/show/NCT02596126 (first received 5 October 2015). 5299613
151. Merat S, Poustchi H, Hemming K, Jafari E, Radmard AR, Nateghi A, et al. PolyPill for prevention of cardiovascular disease in an urban Iranian population with special focus on nonalcoholic steatohepatitis: a pragmatic randomized controlled trial within a cohort (PolyIran - Liver) - study protocol. Archives of Iranian Medicine 2015;18:515-23. 5299614
152. NCT01271985 . Prevention of cardiovascular disease in middle-aged and elderly Iranians using a single polypill (PolyIran). clinicaltrials.gov/ct2/show/NCT01271985 (first received 14 December 2010). 3217202
153. Ostovaneh MR, Poustchi H, Hemming K, Marjani H, Pourshams A, Nateghi A, et al. Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial. European Journal of Preventive Cardiology 2015;22:1609-17. 5299615
154. Roshandel G, Ostovaneh MR, Poustchi H, Malekzadeh F, Sepanlou SG, Honarvar MR, et al. Reliability analysis of a newly developed questionnaire for quality control of follow-up visits in PolyIran study. Archives of Iranian Medicine 2016;19:551-5. 5299616
155. ALLHAT-investigators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981-97.
156. Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R, Rahimi K, et al. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA 2010;303(24):2486-94.
157. ATT-Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71-86.
158. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267-78.
159. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678):1849-60.
160. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. American Journal of Medicine 2007;120:713-8. [PUBMED: 17679131]
161. Beaglehole R, Bonita R, Horton R, Adams C, Alleyne G, Asaria P, et al. Priority actions for the non-communicable disease crisis. Lancet 2011;377(9775):1438-47.
162. Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, et al. Lifetime risks of cardiovascular disease. New England Journal of Medicine 2012;366(4):321-9.
163. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364(9435):685-96.
164. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335(8693):827-38.
165. Cholesterol Treatment Trialists' Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90. [DOI: doi.org/10.1016/S0140-6736(12)60367-5]
166. de Cates AN, Farr MR, Wright N, Jarvis MC, Rees K, Ebrahim S, et al. Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD009868.pub2]
167. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
168. Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD001561.pub3]
169. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
170. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal 2016;37(29):2315-81.
171. Franco OH, Bonneux L, de Laet C, Peeters A, Steyerberg EW, Mackenbach JP. The polymeal: a more natural, safer, and probably tastier (than the polypill) strategy to reduce cardiovascular disease by more than 75%. BMJ 2004;329(7480):1447-50.
172. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59:7-10.
173. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine 2003;348(5):383-93.
174. Schünemann H, Brozek J, Guyatt G, Oxman A (editors). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October 2013. gdt.guidelinedevelopment.org/app/handbook/handbook.html.
175. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55(2):399-407.
176. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
177. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
178. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
179. Holmes MV, Newcombe P, Hubacek JA, Sofat R, Ricketts SL, Cooper J, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 2011;378(9791):584-94.
180. HPSCG . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22.
181. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363(9426):2022-31.
182. Karmali KN, Lloyd-Jones DM, Berendsen MA, Goff DC Jr, Sanghavi DM, Brown NC, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiology 2016;1(3):341-9.
183. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371(9607):117-25.
184. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine 2005;352(14):1425-35.
185. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of InterventionsVersion 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
186. Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation 2010;122(20):2078-88.
187. Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews 2014;3:82.
188. Messerli FH, Bakris GL, Ferrera D, Houston MC, Petrella RJ, Flack JM, et al. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. Journal of Clinical Hypertension 2006;8(8):571-81; quiz 82-3.
189. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Medicine 2009;6(7):e1000097. [DOI: doi:10.1371/journal.pmed1000097]
190. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316, 099 white men. Multiple Risk Factor Intervention Trial Research Group. Archives of Internal Medicine 1992;152(1):56-64.
191. NICE . Lipid Modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. www.nice.org.uk/nicemedia/pdf/CG67NICEguideline.pdf 2008 (Accessed 17 January 2017).
192. NICE . Cardiovascular disease prevention. www.nice.org.uk/guidance/PH25 2010 (Accessed 17 January 2017).
193. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010;376(9735):112-23.
194. Ostergren J, Poulter NR, Sever PS, Dahlof B, Wedel H, Beevers G, et al. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. Journal of Hypertension 2008;26(11):2103-11.
195. Papademetriou V, Piller LB, Ford CE, Gordon D, Hartney TJ, Geraci TS, et al. Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of Clinical Hypertension 2003;5(6):377-84.
196. Perk J, DeBacker G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). European Journal of Cardiology 2012;33:1635-701. [PUBMED: 10.1093/eurheartj/ehs092]
197. PILL-collaborative, Rodgers A, Patel A, Berwanger O, Bots M, Grimm R, et al. An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. Plos One 2011;6(5):e19857.
198. Preston RA, Harvey P, Herfert O, Dykstra G, Jukema JW, Sun F, et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. Journal of Clinical Pharmacology 2007;47(12):1555-69.
199. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003;34(11):2741-8.
200. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. New England Journal of Medicine 2015;372(14):1333-41.
201. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361(9364):1149-58.
202. Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013;129(25 Suppl 2):S1-45. [DOI: 01.cir.0000437738.63853.7a]
203. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD004816.pub5]
204. Thomas F, Bean K, Guize L, Quentzel S, Argyriadis P, Benetos A. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young. European Heart Journal 2002;23(7):528-35.
205. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362(9395):1527-35.
206. Vartiainen E, Laatikainen T, Peltonen M, Juolevi A, Mannisto S, Sundvall J, et al. Thirty-five-year trends in cardiovascular risk factors in Finland. International Journal of Epidemiology 2010;39(2):504-18.
207. Viera AJ, Sheridan SL, Edwards T, Soliman EZ, Harris R, Furberg CD. Acceptance of a polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. Preventive Medicine 2011;52(1):10-5.
208. Virdee SK, Greenfield SM, Fletcher K, McManus RJ, Hobbs FD, Mant J. Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study. BMJ Open 2013;3:e002498.
209. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326(7404):1419.
210. Wald DS, Wald NJ. The polypill in the prevention of cardiovascular disease. Preventive Medicine 2011;52(1):16-7.
211. World Health Organization. Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions. Report of WHO-Wellcome Trust meeting of experts (1-3 August 2001). apps.who.int/iris/bitstream/10665/42567/1/WHO_MPN_CVD_2002.01.pdf 2001.
212. World Health Organization. Global action plan for the prevention and control of noncommunicable diseases, 2013-202. apps.who.int/iris/bitstream/10665/94384/1/9789241506236_eng.pdf 2013;1:1-55.
213. World Health Organization. HEARTS Technical package for cardiovascular disease management in primary health care. www.who.int/cardiovascular_diseases/hearts/Hearts_package.pdf 2016;1:1-76.
214. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002;360(9326):2-3.
215. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):937-52.
216. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey. Lancet 2011;378(9798):1231-43.
217. de Cates AN, Farr MR, Wright N, Jarvis MC, Rees K, Ebrahim S, et al. Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD009868.pub2]